Effects of aripiprazole on prolactin levels and differences in effectiveness in patients with schizophrenia: a post-hoc analysis of the real-world data of a multicenter study

Qian Li, Yun‐Ai Su, Xuemei Liao, Maosheng Fang, Jianliang Gao, Jia Xu, Mingjun Duan, Haiying Yu, Yang Yang, Zhiyu Chen, Jintong Liu, Shaoxiao Yan, Pei-Fen Yao, Shuying Li, Changhong Wang, Bin Wu, Congpei Zhang, Tianmei SiFrontiers in Psychiatry 2024 · DOI

Abstract

In this real-world study, for patients with acute schizophrenia, aripiprazole was effective in lowering the proportion of patients with abnormal prolactin levels, while it had no significant effect on patients with normal baseline prolactin. After adjusting for factors such as sex, age, prior antipsychotic drugs use history and disease severity, effectiveness and safety of aripiprazole in patients with normal baseline prolactin was significantly better than that in patients with elevated baseline prolactin.

Introduction

Most antipsychotic medications work by blocking dopamine D2 receptors. However, because dopamine normally inhibits prolactin secretion in the pituitary gland, blocking these receptors often leads to hyperprolactinemia (HPRL). This side effect can cause distressing issues like sexual dysfunction, bone density loss, and menstrual irregularities, which frequently lead patients to stop taking their medication.

Aripiprazole is unique because it is a D2 receptor partial agonist—it acts as a stabilizer rather than a total blocker. While clinical trials have shown it can lower prolactin, this study addresses a gap in "real-world" knowledge: Does a patient's starting prolactin level change how well the drug works for their psychiatric symptoms? In a clinical setting where patients have diverse treatment histories, understanding this relationship is crucial for personalized medicine.

Methods

Researchers conducted a post-hoc analysis of data from a large, multicenter real-world study involving 14 institutions across China. The analysis included 537 patients who had documented baseline prolactin levels.

Patients were divided into two groups based on baseline serum prolactin (PRL):

  • Elevated-PRL group: ≥ 530 mIU/L (n=64)
  • Normal-PRL group: < 530 mIU/L (n=473)

Patients received 10–30 mg/day of orally disintegrating aripiprazole tablets over 8 weeks. Effectiveness was measured using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) scores, and Medication Satisfaction Questionnaire (MSQ). Safety was monitored via the Udvalg for Kliniske Undersogelser (UKU) Side Effects Rating Scale.

Key Results

Prolactin Modulation

Aripiprazole demonstrated a modulating "thermostat" effect. In the elevated group, the proportion of patients with abnormal prolactin plummeted from 100% to 25% by week 8. Conversely, it had no significant effect on the normal group, suggesting it doesn't push prolactin levels below healthy thresholds.

Clinical Efficacy and Symptom Reduction

Even after adjusting for sex, age, and disease severity, the normal-PRL group showed significantly better symptom reduction across multiple clinical scales.

Clinical improvement over 8 weeks as measured by CGI-S change, CGI-I improvement rate, and MSQ scores.

The normal-PRL group achieved a significantly higher reduction in PANSS total scores compared to the elevated group by the end of the study (-52.90 vs. -45.95, P = 0.0014).

Comparison of PANSS score changes and reduction rates between elevated and normal prolactin groups at weeks 2, 4, and 8.

By week 8, the clinical response rate was 96.6% in the normal group versus 87.8% in the elevated group.

Safety Profile

Adverse events (AEs) were more common in the elevated-PRL group (87.2%) than in the normal-PRL group (71.0%). Common AEs included akathisia (restlessness) and tremors. Baseline prolactin levels did not significantly influence aripiprazole’s effect on metabolic markers like BMI, blood glucose, or lipids, confirming the drug's relatively favorable metabolic profile.

Discussion and Conclusion

The elevated-PRL group tended to have a longer duration of illness and a higher proportion of women, suggesting that high baseline prolactin might be a marker for patients with more extensive prior exposure to other D2-blocking antipsychotics. This implies that baseline prolactin levels might be inversely correlated with the brain's "readiness" to respond to a partial agonist like aripiprazole.

These findings suggest that baseline prolactin might serve as a valuable prognostic biomarker for treatment response in schizophrenia. Patients with normal baseline prolactin levels appear to experience superior clinical improvement and better tolerability. Future prospective, randomized controlled trials are needed to confirm if baseline prolactin can be used as a definitive predictor of treatment success, potentially allowing clinicians to choose aripiprazole earlier for patients with specific biological profiles.

Summary updated

Abstract

In this real-world study, for patients with acute schizophrenia, aripiprazole was effective in lowering the proportion of patients with abnormal prolactin levels, while it had no significant effect on patients with normal baseline prolactin. After adjusting for factors such as sex, age, prior antipsychotic drugs use history and disease severity, effectiveness and safety of aripiprazole in patients with normal baseline prolactin was significantly better than that in patients with elevated baseline prolactin.
BibTeX
@inproceedings{li2024effects,
  author = {Qian Li and Yun‐Ai Su and Xuemei Liao and Maosheng Fang and Jianliang Gao and Jia Xu and Mingjun Duan and Haiying Yu and Yang Yang and Zhiyu Chen and Jintong Liu and Shaoxiao Yan and Pei-Fen Yao and Shuying Li and Changhong Wang and Bin Wu and Congpei Zhang and Tianmei Si},
  title = {{Effects of aripiprazole on prolactin levels and differences in effectiveness in patients with schizophrenia: a post-hoc analysis of the real-world data of a multicenter study}},
  booktitle = {Frontiers in Psychiatry},
  year = {2024},
  doi = {10.3389/fpsyt.2024.1383173},
}
Figure